Huang Ying-Xue, Qi Jinliang, Wang Hong-Sheng, Shao Xue-Bao, Zeng Xue-Si, Li A-Mei, Xu Xiu-Lian, Sun Jian-Fang
Key Laboratory of Molecular Biology for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Sciences.
J Dermatol. 2013 Nov;40(11):901-10. doi: 10.1111/1346-8138.12294. Epub 2013 Sep 23.
The relationship of ovostatin 2 (OVOS2) expression with the clinicopathological features of cutaneous malignant melanoma (CMM) was investigated to identify OVOS2 expression in cutaneous melanocytic lesions, and to reveal whether OVOS2 has a function in melanoma progression. Eight specimens of CMM and paracancerous tissue were analyzed using real-time polymerase chain reaction (PCR) and western blot for the mRNA and protein expression of OVOS2, respectively. Immunohistochemical staining was performed on 52 CMM and 62 nevi, followed by clinicopathological significance analysis. The proliferative cells were visualized by staining with Ki-67 antibody. The intensity of angiogenesis was assessed by staining with vascular endothelial growth factor (VEGF). Real-time PCR and western blot analyses showed that OVOS2 was significantly upregulated in cutaneous melanoma than in paired normal skins. Immunohistochemistry showed that 86.5% (45/52) of malignant cases showed OVOS2 cytoplasmic expression compared with 29% (18/62) in benign nevi. OVOS2 expression was significantly higher in invasive and metastatic melanoma than in in situ melanoma (P < 0.01). Furthermore, OVOS2 expression was positively correlated with the known prognostic variables of melanoma including clinical stage, Clark level and Breslow depth. It was also significantly associated with ulcer status, Ki-67 labeling index and VEGF expression in primary melanoma. OVOS2 expression was significantly increased in CMM, which increased incrementally from benign nevi to melanoma and appeared to be involved in the progression of melanoma.
研究了抑卵素2（OVOS2）表达与皮肤恶性黑色素瘤（CMM）临床病理特征的关系，以确定皮肤黑素细胞病变中OVOS2的表达，并揭示OVOS2在黑色素瘤进展中是否具有作用。分别使用实时聚合酶链反应（PCR）和蛋白质免疫印迹法分析8例CMM标本和癌旁组织中OVOS2的mRNA和蛋白质表达。对52例CMM和62例痣进行免疫组织化学染色，随后进行临床病理意义分析。用Ki-67抗体染色使增殖细胞可视化。用血管内皮生长因子（VEGF）染色评估血管生成强度。实时PCR和蛋白质免疫印迹分析表明，与配对的正常皮肤相比，皮肤黑色素瘤中OVOS2显著上调。免疫组织化学显示，86.5%（45/52）的恶性病例有OVOS2细胞质表达，而良性痣中这一比例为29%（18/62）。侵袭性和转移性黑色素瘤中OVOS2表达显著高于原位黑色素瘤（P<0.01）。此外，OVOS2表达与黑色素瘤已知的预后变量呈正相关，包括临床分期、克拉克分级和 Breslow 深度。它还与原发性黑色素瘤的溃疡状态、Ki-67标记指数和VEGF表达显著相关。CMM中OVOS2表达显著增加，从良性痣到黑色素瘤逐渐增加，似乎参与了黑色素瘤的进展。
